Should I buy or sell EyePoint Pharmaceuticals stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for EyePoint Pharmaceuticals in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EYPT shares. View EYPT analyst ratings or view top-rated stocks .

What is EyePoint Pharmaceuticals' stock price target for 2024?

7 Wall Street research analysts have issued twelve-month target prices for EyePoint Pharmaceuticals' stock. Their EYPT share price targets range from $22.00 to $44.00. On average, they expect the company's stock price to reach $33.86 in the next twelve months. This suggests a possible upside of 94.4% from the stock's current price. View analysts price targets for EYPT or view top-rated stocks among Wall Street analysts .

How have EYPT shares performed in 2024?

EyePoint Pharmaceuticals' stock was trading at $23.11 at the start of the year. Since then, EYPT stock has decreased by 24.6% and is now trading at $17.42. View the best growth stocks for 2024 here .

When is EyePoint Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our EYPT earnings forecast .

How were EyePoint Pharmaceuticals' earnings last quarter?

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) announced its earnings results on Thursday, March, 7th. The company reported ($0.33) earnings per share for the quarter, beating analysts' consensus estimates of ($0.60) by $0.27. The business had revenue of $14.03 million for the quarter, compared to analysts' expectations of $8.71 million. EyePoint Pharmaceuticals had a negative net margin of 153.84% and a negative trailing twelve-month return on equity of 61.48%. During the same period last year, the business earned ($0.61) earnings per share.

What ETFs hold EyePoint Pharmaceuticals' stock?

ETFs with the largest weight of EyePoint Pharmaceuticals (NASDAQ:EYPT) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Invesco Biotechnology & Genome ETF (PBE) . Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) .

When did EyePoint Pharmaceuticals' stock split?

Shares of EyePoint Pharmaceuticals reverse split on Wednesday, December 9th 2020. The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, December 9th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of EyePoint Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other EyePoint Pharmaceuticals investors own include Sorrento Therapeutics (SRNE) , OPKO Health (OPK) , Inovio Pharmaceuticals (INO) , Verastem (VSTM) , XOMA (XOMA) , AcelRx Pharmaceuticals (ACRX) , Catalyst Pharmaceuticals (CPRX) , Progenics Pharmaceuticals (PGNX) , Corbus Pharmaceuticals (CRBP) and Dynavax Technologies (DVAX) .

Who are EyePoint Pharmaceuticals' major shareholders?

EyePoint Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Woodstock Corp (0.06%). Insiders that own company stock include Cormorant Asset Management, Lp, Dario A Paggiarino, David Scott Jones, Ew Healthcare Partners, LP, Michael Craig Pine and Ye Liu. View institutional ownership trends .

How do I buy shares of EyePoint Pharmaceuticals?

Shares of EYPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:EYPT

EyePoint Pharmaceuticals (EYPT) Stock Price, News & Analysis

→ Don’t expose yourself to stocks during the week (From DTI) (Ad)

Free EYPT Stock Alerts

$17.56

+0.06 (+0.34%)

(As of 03:21 PM ET)

Compare

Today's Range: $16.71
▼
$17.80
50-Day Range: $17.50
▼
$29.71
52-Week Range: $5.32
▼
$30.99

Volume: 1.24 million shs
Average Volume: 990,038 shs
Market Capitalization: $875.03 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $33.86

Get EyePoint Pharmaceuticals alerts:

EyePoint Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 94.4% Upside
$33.86 Price Target
Short Interest: Bearish
13.75% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.73
Based on 6 Articles This Week
Insider Trading: Selling Shares
$1.44 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.73) to ($2.59) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.78 out of 5 stars

Medical Sector

580th out of 918 stocks

Analytical Instruments Industry

21st out of 26 stocks

3.5

Analyst's Opinion

Consensus Rating
EyePoint Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
EyePoint Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
13.75% of the outstanding shares of EyePoint Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
EyePoint Pharmaceuticals has a short interest ratio ("days to cover") of 7.1.
Change versus previous month
Short interest in EyePoint Pharmaceuticals has recently increased by 4.10%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
EyePoint Pharmaceuticals does not currently pay a dividend.
Dividend Growth
EyePoint Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for EYPT.

2.6

News and Social Media Coverage

News Sentiment
EyePoint Pharmaceuticals has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for EyePoint Pharmaceuticals this week, compared to 4 articles on an average week.
Search Interest
Only 9 people have searched for EYPT on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added EyePoint Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, EyePoint Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,437,509.00 in company stock.
Percentage Held by Insiders
13.05% of the stock of EyePoint Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
99.41% of the stock of EyePoint Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for EyePoint Pharmaceuticals are expected to decrease in the coming year, from ($1.73) to ($2.59) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of EyePoint Pharmaceuticals is -9.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of EyePoint Pharmaceuticals is -9.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
EyePoint Pharmaceuticals has a P/B Ratio of 3.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About EyePoint Pharmaceuticals Stock (NASDAQ:EYPT)

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

EYPT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EYPT Stock News Headlines

April 19, 2024 | markets.businessinsider.com

Buy Recommendation: EyePoint Pharmaceuticals’ Promising Outlook with EYP-1901 for Diabetic Retinopathy and AMD

April 16, 2024 | globenewswire.com

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

April 19, 2024 | Darwin (Ad)

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

April 13, 2024 | markets.businessinsider.com

Strong Buy Rating for EyePoint Pharmaceuticals Amid Promising Developments in Ophthalmic Therapies

April 12, 2024 | americanbankingnews.com

EyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Down to $21.53

April 12, 2024 | americanbankingnews.com

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Recommendation of "Buy" from Brokerages

April 2, 2024 | globenewswire.com

EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists

March 18, 2024 | globenewswire.com

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

April 19, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

March 9, 2024 | finance.yahoo.com

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Analysts Just Slashed This Year's Revenue Estimates By 22%

March 8, 2024 | markets.businessinsider.com

Buy Rating Affirmed for EyePoint Pharmaceuticals Amidst Promising Clinical Trials and Market Expansion Potential

March 8, 2024 | markets.businessinsider.com

Critical Insights From EyePoint Pharmaceuticals Analyst Ratings: What You Need To Know

March 8, 2024 | finance.yahoo.com

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Call Transcript

March 8, 2024 | finance.yahoo.com

EyePoint Pharmaceuticals Full Year 2023 Earnings: Beats Expectations

March 8, 2024 | finance.yahoo.com

Q4 2023 EyePoint Pharmaceuticals Inc Earnings Call

March 7, 2024 | finance.yahoo.com

EyePoint Pharmaceuticals Inc (EYPT) Reports Growth Amidst Strategic Shifts in Q4 and Full-Year 2023

March 7, 2024 | investorplace.com

EYPT Stock Earnings: EyePoint Pharmaceuticals Beats EPS, Beats Revenue for Q4 2023

March 7, 2024 | seekingalpha.com

EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2023 Earnings Conference Call Transcript

March 7, 2024 | msn.com

EyePoint Pharmaceuticals GAAP EPS of -$0.33 beats by $0.16, revenue of $14M beats by $5.3M

March 7, 2024 | markets.businessinsider.com

EyePoint Pharmaceuticals: Strategic Leadership Appointment and Positive Developments Bolster Buy Rating

March 7, 2024 | washingtonpost.com

EyePoint Pharmaceuticals: Q4 Earnings Snapshot

March 7, 2024 | globenewswire.com

EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments

March 6, 2024 | msn.com

EyePoint Pharmaceuticals Q4 2023 Earnings Preview

March 6, 2024 | benzinga.com

A Preview Of EyePoint Pharmaceuticals's Earnings

March 5, 2024 | markets.businessinsider.com

Buy Rating Affirmed for EyePoint Pharmaceuticals Amid Strategic Leadership Changes and Promising Pipeline Outlook

March 4, 2024 | finanznachrichten.de

EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer

March 4, 2024 | globenewswire.com

EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer

See More Headlines

Receive EYPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/07/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Analytical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:EYPT
CUSIP: N/A
CIK: 1314102
Web: eyepointpharma.com
Phone: (617) 926-5000
Fax: 617-926-5050
Employees: 121
Year Founded: 1987

Price Target and Rating

Average Stock Price Target: $33.86
High Stock Price Target: $44.00
Low Stock Price Target: $22.00
Potential Upside/Downside: +93.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.83)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-70,790,000.00
Net Margins: -153.84%
Pretax Margin: -153.66%
Return on Equity: -61.48%
Return on Assets: -33.49%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.45
Quick Ratio: 5.39

Sales & Book Value

Annual Sales: $46.02 million
Price / Sales: 18.95
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.66 per share
Price / Book: 3.09

Miscellaneous

Outstanding Shares: 49,830,000
Free Float: 43,328,000
Market Cap: $872.03 million
Optionable: Optionable
Beta: 1.64

Social Links

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Dr. Jay S. Duker M.D. (Age 65)
President, CEO & Director
Comp: $848.5k
Dr. John B. Landis M.S. (Age 71)
Ph.D., Interim Head of R&D and Director
Comp: $63.75k
Mr. Michael Pine (Age 47)
Chief Business Officer
Comp: $764.85k
Mr. George O. Elston (Age 59)
Executive VP & CFO
Comp: $743.86k
Mr. Michael J. Maciocio
Senior Vice President of Manufacturing & Operations
Mr. Ron I. Honig Esq.
Chief Legal Officer & Company Secretary
Ms. Jennifer Leonard
Chief People Officer & Senior VP of IT
Mr. David Scott Jones (Age 56)
Senior VP & Chief Commercial Officer
Comp: $672.08k
Ms. Isabelle Lefebvre
Chief Regulatory Officer
Dr. Marcia Sellos-Moura Ph.D.
Senior Vice President of Program Leadership

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

EYPT Stock Analysis - Frequently Asked Questions

Should I buy or sell EyePoint Pharmaceuticals stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for EyePoint Pharmaceuticals in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EYPT shares.
View EYPT analyst ratings or view top-rated stocks.
What is EyePoint Pharmaceuticals' stock price target for 2024?: 7 Wall Street research analysts have issued twelve-month target prices for EyePoint Pharmaceuticals' stock. Their EYPT share price targets range from $22.00 to $44.00. On average, they expect the company's stock price to reach $33.86 in the next twelve months. This suggests a possible upside of 94.4% from the stock's current price.
View analysts price targets for EYPT or view top-rated stocks among Wall Street analysts.
How have EYPT shares performed in 2024?: EyePoint Pharmaceuticals' stock was trading at $23.11 at the start of the year. Since then, EYPT stock has decreased by 24.6% and is now trading at $17.42.
View the best growth stocks for 2024 here.
When is EyePoint Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our EYPT earnings forecast.
How were EyePoint Pharmaceuticals' earnings last quarter?: EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) announced its earnings results on Thursday, March, 7th. The company reported ($0.33) earnings per share for the quarter, beating analysts' consensus estimates of ($0.60) by $0.27. The business had revenue of $14.03 million for the quarter, compared to analysts' expectations of $8.71 million. EyePoint Pharmaceuticals had a negative net margin of 153.84% and a negative trailing twelve-month return on equity of 61.48%. During the same period last year, the business earned ($0.61) earnings per share.
What ETFs hold EyePoint Pharmaceuticals' stock?: ETFs with the largest weight of EyePoint Pharmaceuticals (NASDAQ:EYPT) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Invesco Biotechnology & Genome ETF (PBE).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).

When did EyePoint Pharmaceuticals' stock split?: Shares of EyePoint Pharmaceuticals reverse split on Wednesday, December 9th 2020. The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, December 9th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What other stocks do shareholders of EyePoint Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other EyePoint Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), Inovio Pharmaceuticals (INO), Verastem (VSTM), XOMA (XOMA), AcelRx Pharmaceuticals (ACRX), Catalyst Pharmaceuticals (CPRX), Progenics Pharmaceuticals (PGNX), Corbus Pharmaceuticals (CRBP) and Dynavax Technologies (DVAX).
Who are EyePoint Pharmaceuticals' major shareholders?: EyePoint Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Woodstock Corp (0.06%). Insiders that own company stock include Cormorant Asset Management, Lp, Dario A Paggiarino, David Scott Jones, Ew Healthcare Partners, LP, Michael Craig Pine and Ye Liu.
View institutional ownership trends.
How do I buy shares of EyePoint Pharmaceuticals?: Shares of EYPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EYPT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

EyePoint Pharmaceuticals (EYPT) Stock Price, News & Analysis

EyePoint Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About EyePoint Pharmaceuticals Stock (NASDAQ:EYPT)

EYPT Stock Price History

EYPT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

EYPT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™